Phar 443 Exam #2 Darrell's Drugs And Some Details

Front 1

blocks VMAT2?

Back 1

reserpine

Front 2

blocks DAT?

Back 2

cocaine

Front 3

sympathetic neurons do not have which NT breakdown catalyst?

Back 3

COMT

Front 4

tri-cyclic antidepressants block?

Back 4

NET

Front 5

additional enzyme required to synthesize epinephrine?

Back 5

PNMT

Front 6

12 membrane spanning domains describe what?

Back 6

VMAT2, DAT, NET

(transporters)

Front 7

VMAT2 needs what to function?

Back 7

protons inside vesicle and ATP powered proton pump to pump them out

Front 8

what do the transporters DAT and NET depend on?

Back 8

sodium gradient

Front 9

which forms of MAO exist?

Back 9

A and B

Front 10

what can those on MAO's not eat?

Back 10

dairy products

Front 11

oxymetazoline

Back 11

adrenergic agonist, direct-acting, non-selective, alpha-1,2

Front 12

ephedrine

Back 12

adrenergic agonist, mixed-acting, alpha-1,2, beta-1,2 and releasing agent

Front 13

amphetamine

Back 13

adrenergic agonist, indirect-acting, releasing agent

Front 14

tyramine

Back 14

adrenergic agonist, indirect-acting, releasing agent

Front 15

cocaine

Back 15

adrenergic agonist, indirect-acting, uptake inhibitor

Front 16

selegiline

Back 16

adrenergic agonist, indirect-acting, MAO inhibitor (B form)

Front 17

corgyline

Back 17

adrenergic agonist, indirect-acting, MAO inhibitor (A form)

Front 18

pargyline

Back 18

adrenergic agonist, indirect-acting, MAO inhibitor (B form)

Front 19

entacapone

Back 19

adrenergic agonist, indirect-acting, COMT inhibitor

Front 20

pyrogallol

Back 20

adrenergic agonist, indirect-acting, COMT inhibitor

Front 21

tropolone

Back 21

adrenergic agonist, indirect-acting, COMT inhibitor

Front 22

responses are not reduced by prior treatment with reserpine or guanethidine but may be potentiated by cocaine, reserpine, and guanethidine for which categories?

Back 22

selective and non-selective, direct acting, adrenergic agonists

Front 23

response is reduced by prior treatment with reserpine or guanethidine?

Back 23

mixed acting, adrenergic agonists (ephedrine)

Front 24

responses are abolished by prior treatment with reserpine or guanethidine?

Back 24

indirect-acting, adrenergic agonists that are releasing agents (amphetamine, tyramine)

Front 25

phenoxybenzamine

Back 25

adrenergic antagonist, alpha receptor, non-selective

irreversible via covalent modification

Front 26

phentolamine

Back 26

adrenergic antagonist, alpha receptor, non-selective

reversible

Front 27

prazosin*

Back 27

adrenergic antagonist, alpha receptor, alpha-1 selective

vascular resistance control

more effective in alpha-1 than alpha-2 (1000 times)

lasts 7-10 hours

Front 28

terazosin*

Back 28

adrenergic antagonist, alpha receptor, alpha-1 selective

vascular resistance control

better for BPH than prazosin because higher affinity for alpha-1a receptor

Front 29

doxazosin*

Back 29

adrenergic antagonist, alpha receptor, alpha-1 selective

vascular resistance control

good for BPH, high selectivity for alpha-1, long lasting (not necessarily good)

Front 30

alfuzosin*

Back 30

adrenergic antagonist, alpha receptor, alpha-1 selective

vascular resistance control

good for BPH, similar affinity for all alpha-1 receptors, shorter acting

Front 31

tamsulosin*

Back 31

adrenergic antagonist, alpha receptor, alpha-1 selective

vascular resistance control

used to treat BPH w/ little effect on BP, selective for alpha-1a,d over b

Front 32

indoramin

Back 32

adrenergic antagonist, alpha receptor, alpha-1 selective

vascular resistance control

Front 33

urapidil

Back 33

adrenergic antagonist, alpha receptor, alpha-1 selective

vascular resistance control

Front 34

bunazosin

Back 34

adrenergic antagonist, alpha receptor, alpha-1 selective

vascular resistance control

Front 35

yohimbine*

Back 35

adrenergic antagonist, alpha receptor, alpha-2 selective

pulled off market, now supplement

increase in blood pressure and HR

Front 36

nadolol*

Back 36

adrenergic antagonist, beta receptor, non-selective, first generation

membrane stabilization properties via blockage of voltage gated Na channels

treats HTN, angina and is long acting

Front 37

penbutolol

Back 37

adrenergic antagonist, beta receptor, non-selective, first generation

membrane stabilization properties via blockage of voltage gated Na channels

Front 38

pindolol*

Back 38

adrenergic antagonist, beta receptor, non-selective, first generation

membrane stabilization properties via blockage of voltage gated Na channels

treats HTN, angina, 4 hr half life

Front 39

propranolol*

Back 39

adrenergic antagonist, beta receptor, non-selective, first generation

membrane stabilization properties via blockage of voltage gated Na channels

treats HTN, angina, arrhythmias/tachycardia

some intrinsic sympathetic activity causing bronchodilation in normal pt

Front 40

timolol*

Back 40

adrenergic antagonist, beta receptor, non-selective, first generation

membrane stabilization properties via blockage of voltage gated Na channels

treats HTN, CHF, acute MI, migraine, open angle glaucoma, intraocular HTN

Front 41

sotalol

Back 41

adrenergic antagonist, beta receptor, non-selective, first generation

membrane stabilization properties via blockage of voltage gated Na channels

Front 42

levobunolol

Back 42

adrenergic antagonist, beta receptor, non-selective, first generation

membrane stabilization properties via blockage of voltage gated Na channels

Front 43

metipranolol

Back 43

adrenergic antagonist, beta receptor, non-selective, first generation

membrane stabilization properties via blockage of voltage gated Na channels

Front 44

acebutolol*

Back 44

adrenergic antagonist, beta receptor, beta-1 selective, second generation

treats HTN, ventricular/atrial arrhythmias, acute MI, some intrinsic sympathetic activity and membrane stabilization activity

Front 45

atenolol*

Back 45

adrenergic antagonist, beta receptor, beta-1 selective, second generation

treats HTN, CHD, angina, no intrinsic sympathetic activity and membrane stabilization activity

Front 46

bisoprolol*

Back 46

adrenergic antagonist, beta receptor, beta-1 selective, second generation

treats HTN, has better beta-1 selectivity than other drugs besides nebivolol so better for COPD (check?), no intrinsic sympathetic activity and membrane stabilization activity

Front 47

esmolol*

Back 47

adrenergic antagonist, beta receptor, beta-1 selective, second generation

treat critically ill pt (given IV) with need for rapid onset and short duration, watch out for bradycardia, heart failure, hypotension, no intrinsic sympathetic activity and membrane stabilization activity

Front 48

metoprolol*

Back 48

adrenergic antagonist, beta receptor, beta-1 selective, second generation

treats essential HTN, preventing MI, adjunct for hyperthyroidism, migraine, no intrinsic sympathetic activity or membrane stabilization

Front 49

carteolol*

Back 49

adrenergic antagonist, beta receptor, non-selective, third generation

beta-2 agonist properties

Front 50

carvedilol*

Back 50

adrenergic antagonist, beta receptor, non-selective, third generation

alpha-1 adrenergic receptor blockade

Ca2+ entry blockade

antioxidant and anti-inflammatory action

Front 51

bucindolol

Back 51

adrenergic antagonist, beta receptor, non-selective, third generation

Front 52

labetalol*

Back 52

adrenergic antagonist, beta receptor, non-selective, third generation

alpha-1 adrenergic receptor blockade

Front 53

betaxolol*

Back 53

adrenergic antagonist, beta receptor, beta-1 selective, third generation

treats HTN, angina, glaucoma (reduces production of aqueous humor), slight membrane stabilization activity

Front 54

celiprolol*

Back 54

adrenergic antagonist, beta receptor, beta-1 selective, third generation

increased production of NO

beta-2 agonist properties

Front 55

nebivolol*

Back 55

adrenergic antagonist, beta receptor, beta-1 selective, third generation

increased production of NO

Front 56

nipradolol*

Back 56

increased production of NO

Front 57

tilisolol*

Back 57

opening of K+ channels

Front 58

phenylephrine

Back 58

adrenergic agonist, direct acting, selective, alpha-1

Front 59

metaraminol

Back 59

adrenergic agonist, direct acting, selective, alpha-1

rapid

Front 60

midodrine

Back 60

adrenergic agonist, direct acting, selective, alpha-1

prodrug, do not give to elderly

Front 61

clonidine

Back 61

adrenergic agonist, direct acting, selective, alpha-2

Front 62

apraclonidine

Back 62

adrenergic agonist, direct acting, selective, alpha-2

Front 63

brimonidine

Back 63

adrenergic agonist, direct acting, selective, alpha-2

Front 64

guanabenz

Back 64

adrenergic agonist, direct acting, selective, alpha-2

Front 65

tizanidine

Back 65

adrenergic agonist, direct acting, selective, alpha-2

Front 66

dobutamine

Back 66

adrenergic agonist, direct acting, selective, beta-1

Front 67

terbutaline

Back 67

adrenergic agonist, direct acting, selective, beta-2

SABA

Front 68

albuterol

Back 68

adrenergic agonist, direct acting, selective, beta-2

SABA

Front 69

salmeterol

Back 69

adrenergic agonist, direct acting, selective, beta-2

LABA

Front 70

formoterol

Back 70

adrenergic agonist, direct acting, selective, beta-2

LABA

Front 71

epinephrine

Back 71

adrenergic agonist, direct acting, non-selective, alpha-1,2, beta-1,2

greater affinity for beta-2

Front 72

norepinephrine

Back 72

adrenergic agonist, direct acting, non-selective, alpha-1,2, beta-1

greater affinity for alpha-1,2, beta-1

Front 73

isoproterenol

Back 73

adrenergic agonist, direct acting, non-selective, beta-1,2

Front 74

alpha-1 adrenergic receptor blockade drugs

Back 74

labetalol, carvedilol

Front 75

increased production of NO drugs

Back 75

celiprolol, nebivolol, nipradolol

Front 76

beta-2 agonist properties

Back 76

celiprolol, carteolol

Front 77

Ca2+ entry blockade

Back 77

carvedilol

Front 78

opening of K+ channels

Back 78

tilisolol

Front 79

antioxidant and anti-inflammatory action

Back 79

carvedilol